Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the irritable bowel syndrome drug market will more than triple from $459 million in 2008 to $1.52 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Irritable Bowel Syndrome reveal that the primary driver of market growth will be the launches of several novel first-in-class therapies including Salix's Xifaxan, Ironwood/Forest/Almirall/Astellas's linaclotide, Tioga/Ono's asimadoline and Lexicon/Symphony Icon's LX-1031, beginning in the U.S. in 2011. Two of these therapies - linaclotide and asimadoline - have the potential to treat both motility and pain symptoms associated with irritable bowel syndrome, which will afford them a distinct advantage over currently available drugs.

"Linaclotide will enter the highly underserved market for constipation-predominant irritable bowel syndrome and with launches anticipated in both the U.S. and Europe, we forecast that it will be a major contributor to market growth," said Decision Resources Analyst Iva Holder, Ph.D. "Although linaclotide will capture a relatively small percentage of the total patient share, it will account for 40 percent of overall market sales in 2018 due to its premium pricing."

The Pharmacor 2010 findings also reveal that concerns about the serious side effects associated with 5-HT-receptor-modulating therapies have created a much stricter and challenging regulatory environment for developers of treatments for irritable bowel syndrome. As a result, few new therapies have reached the market in recent years, which has limited the number of safe and effective therapeutic options, particularly for patients who have the most severe and/or refractory form of the disease. The suboptimal efficacy of many of the treatment options available to patients creates significant opportunity for the development of novel therapies for the indication.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,

Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer

View Now